Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research

Contributed by: Business Wire

Logo

Tags

Hardware

Technology

Stem Cells

Radiology

Pharmaceutical

Surgery

Oncology

Professional Services

Medical Devices

Artificial Intelligence

Biotechnology

Science

Software

Data Analytics

Research

Health

commercial agreement with Servier

More Like This

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer

PR Newswire associated0

Appointment of Silvère Lucquin as Chief Executive Officer of Okomera

AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier

PR Newswire associated0

Servier completes the acquisition of Day One Biopharmaceuticals

PR Newswire associated0

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

The IRO platform

Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies